Severe adverse skin reaction and desensitization to sorafenib

Sorafenib is a multikinase inhibitor that targets various receptor tyrosine kinases and RAF kinases (serine/threonine kinases) associated with tumor growth. The most common adverse reactions (≥20%) for sorafenib are diarrhea, fatigue, infection, alopecia, hand-foot skin reaction, rash, weight loss, decreased appetite, nausea, gastrointestinal and abdominal pains, hypertension, and hemorrhage. Severe skin reactions may require dose reduction or even discontinuation of the therapy.1 We report a case of a patient in whom continuation of sorafenib treatment was required despite suspected sorafenib-induced fever and generalized urticaria.

from #ENT via xlomafota13 on Inoreader http://ift.tt/298oYs3
via IFTTT